-
.
- Novo Nordisk A/S NVO revealed heading results from the leader and also stage 3b test of dental semaglutide 25 mg and also 50 mg as an add-on to a steady dosage of 1– 3 dental antidiabetic medications in kind 2 diabetes mellitus clients.
- When reviewing the results of therapy taken as planned and also from a mean standard HbA1c of 9.0 %, 25 mg and also 50 mg dental semaglutide attained an HbA1c decrease of 1.9 and also 2.2 portion factors, specifically, compared to a decrease of 1.5 portion factors with dental semaglutide 14 mg.
- From a mean standard body weight of 96.4 kg, dental semaglutide 25 mg and also 50 mg experienced a statistically substantial greater weight management of 7.0 kg and also 9.2 kg, specifically, compared to a decrease of 4.5 kg with dental semaglutide 14 mg.
- Connected: Novo Nordisk Suspended From UK Profession Organization For Technique Breaches
- When using the therapy plan estimand, 25 mg and also 50 mg dental semaglutide attained an HbA1c decrease of 1.8 and also 2.0 portion factors, specifically, compared to a decrease of 1.5 portion factors with dental semaglutide 14 mg.
- Weight-loss of 6.7 kg and also 8.0 kg for semaglutide 25 mg and also 50 mg, specifically, compared to a decrease of 4.4 kg at 14 mg dosage toughness.
- .
- .(* )The worldwide roll-out of the 25 and also 50 mg dosages is contingent on profile prioritisations and also producing capability.
- Cost Activity:
-
.
© 2023 Benzinga.com. Benzinga does not give financial investment suggestions. All civil liberties booked.
.
.
.
.
.
.(* )All dosages of dental semaglutide showed up to have a secure and also well-tolerated account. One of the most typical damaging occasions were stomach. The substantial bulk were light to modest.
Novo Nordisk anticipates to apply for regulative authorizations in the united state and also the EU in 2023.
.
NVO shares are up 2.60% at $152.25 on the last check Friday.
